首頁 > 市場調查報告書 > 製藥

癌症

免疫腫瘤市場規模、佔有率和成長分析（按治療類型、疾病類型、通路和地區分類）－產業預測，2026-2033年

市場調查報告書

商品編碼

1897947

免疫腫瘤市場規模、佔有率和成長分析（按治療類型、疾病類型、通路和地區分類）－產業預測，2026-2033年

Immuno-Oncology Drugs Market Size, Share, and Growth Analysis, By Treatment Type (Immune Checkpoint Inhibitors, Immune System Modulators), By Disease Type (Melanoma, Lung Cancer), By Distribution Channel, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月19日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計到 2024 年，全球免疫腫瘤藥物市場規模將達到 272.6 億美元，到 2025 年將成長至 322.7 億美元，到 2033 年將成長至 1,246.3 億美元，預測期（2026-2033 年）的複合年成長率為 18.4%。

免疫腫瘤市場正迅速擴張，因為它提供根據每位患者的基因譜、腫瘤特徵和免疫反應量身定做的個人化治療方案。與傳統癌症療法相比，這種治療策略不僅提高了存活率並減少了副作用，而且還引入了具有長期緩解潛力的創新治療選擇。免疫腫瘤藥物透過特異性靶向癌細胞，保護健康組織，並將損害患者生活品質的有害副作用降至最低。它們利用免疫系統發揮持續抗腫瘤活性的獨特能力，改善了患者的整體預後，使免疫腫瘤藥物成為癌症治療領域的變革力量。因此，它們正成為治療各種癌症的首選方案，並有助於改善長期治療策略。

推動全球免疫腫瘤藥物市場發展的因素

全球免疫腫瘤藥物市場的成長主要受監管核准流程的驅動。監管機構的核准至關重要，因為檢驗了免疫腫瘤療法的安全性和有效性，使其得以在醫療保健領域銷售和使用。這種核准不僅透過證明治療方法已經過全面測試而讓投資者和製藥公司放心，而且還刺激了該領域的進一步投資和創新。因此，隨著新的免疫腫瘤藥物核准，患者將更容易獲得先進的療法，從而促進醫療保健機構的廣泛應用，並改善患者的治療效果。

全球免疫腫瘤藥物市場面臨的限制因素

限制全球免疫腫瘤藥物市場成長的一大主要因素是這些療法的高昂費用。免疫腫瘤藥物的高價可能對病患和醫療服務提供者構成重大障礙，尤其是在醫療資源匱乏的地區。這種經濟壁壘可能會限制這些藥物的廣泛應用，從而阻礙市場擴張。此外，高成本也可能影響保險公司和政府醫療計劃將這些療法納入醫保範圍的意願，從而限制患者獲得治療的機會，進一步阻礙市場成長。

全球免疫腫瘤藥物市場趨勢

全球免疫腫瘤藥物市場的一大趨勢是日益重視生物標記的開發和應用。這些生物標記能夠幫助腫瘤學家識別具有特定免疫腫瘤療法良好反應遺傳傾向的患者，從而在癌症個體化治療中發揮關鍵作用。隨著該領域研究的不斷深入，生物標記的應用不僅能夠最佳化患者篩選，還能動態監測治療進展，並根據個別反應及時調整治療方案。這種向精準醫療的轉變旨在最佳化治療效果、最大限度地減少副作用，並最終改善癌症患者的治療結果，因此，生物標記已成為不斷發展的免疫腫瘤學領域的重要關注點。

Coloplast Corp（Denmark）
Bristol Myers Squibb Company（US）
Novartis AG（Switzerland）
F. Hoffmann-La Roche Ltd.（Switzerland）
Merck & Co., Inc.（US）
GSK Plc.（UK）
Eli Lilly and Company（US）
Fresenius Kabi AG（Germany）
Pfizer Inc.（US）
AbbVie Inc.（US）
Genentech Inc.（US）
Sanofi（France）
AstraZeneca（UK）
Bayer AG（Germany）
Bluebird Bio, Inc.（US）
Regeneron Pharmaceuticals, Inc.（US）
Amgen Inc.（US）
Johnson & Johnson（US）
Merck KGaA（Germany）
Ipsen（France）

結論與建議

簡介目錄

Product Code: SQMIG35I2108

Global Immuno-Oncology Drugs Market size was valued at USD 27.26 Billion in 2024 and is poised to grow from USD 32.27 Billion in 2025 to USD 124.63 Billion by 2033, growing at a CAGR of 18.4% during the forecast period (2026-2033).

The market for immuno-oncology drugs is rapidly expanding as they offer a personalized treatment approach tailored to each patient's genetic profile, tumor traits, and immune response. This therapeutic strategy not only leads to increased survival rates and fewer side effects compared to conventional cancer therapies but also introduces innovative treatment options with the potential for long-lasting remission. By specifically targeting cancer cells, immuno-oncology agents preserve healthy tissue, minimizing adverse effects that compromise patients' quality of life. Their unique ability to harness the immune system for sustained anti-tumor activity enhances overall patient outcomes, positioning immuno-oncology drugs as a transformative force in cancer care. Consequently, they are becoming a preferred choice for managing various cancer types while improving long-term management strategies.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Immuno-Oncology Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Immuno-Oncology Drugs Market Segments Analysis

Global Immuno-Oncology Drugs Market is segmented by treatment type, disease type, distribution channel and region. Based on treatment type, the market is segmented into immune checkpoint inhibitors, immune system modulators, cancer vaccines, oncolytic virus and others. Based on disease type, the market is segmented into melanoma, lung cancer, blood cancer, renal cell carcinoma, prostate cancer, bladder cancer and others. Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies and online pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Immuno-Oncology Drugs Market

The growth of the global Immuno-Oncology drugs market is significantly fueled by the regulatory approval process for these therapies. Such endorsements from regulatory bodies are essential, as they validate the safety and efficacy of immuno-oncology treatments, allowing them to be marketed and utilized in healthcare settings. This approval not only reassures investors and pharmaceutical companies by demonstrating that the drugs have undergone thorough testing, but also encourages further investment and innovation in this field. Consequently, as new immuno-oncology drugs gain approval, it enhances patient access to advanced treatments, leading to greater adoption among healthcare providers and improved outcomes for patients.

Restraints in the Global Immuno-Oncology Drugs Market

A significant constraint potentially affecting the growth of the global immuno-oncology drugs market is the prohibitive cost associated with these therapies. The high price tag of immuno-oncology drugs can create substantial obstacles for patients and healthcare providers alike, particularly in regions where affordable healthcare is not readily accessible. This financial barrier may restrict the widespread adoption of these drugs, thus hindering market expansion. Furthermore, the elevated costs can influence the readiness of insurance companies and government healthcare programs to include these treatments in their coverage plans, consequently limiting patient access and further impeding market growth.

Market Trends of the Global Immuno-Oncology Drugs Market

A prominent trend in the Global Immuno-Oncology Drugs market is the increasing emphasis on the development and integration of biomarkers. These biological indicators play a crucial role in personalizing cancer treatment by allowing oncologists to identify patients who are genetically predisposed to respond favorably to specific immuno-oncology therapies. As research in this area advances, the use of biomarkers not only enhances patient selection but also facilitates dynamic treatment monitoring, enabling timely adjustments to therapy based on individual responses. This shift towards precision medicine aims to optimize treatment efficacy, minimize adverse effects, and ultimately improve patient outcomes in cancer care, making biomarkers an essential focus in the evolving landscape of immuno-oncology.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Regulatory Analysis
Case Study Analysis
Patent Analysis

Global Immuno-Oncology Drugs Market Size by Treatment Type & CAGR (2026-2033)

Market Overview
Immune Checkpoint Inhibitors
Immune System Modulators
Cancer Vaccines
Oncolytic Virus
Others

Global Immuno-Oncology Drugs Market Size by Disease Type & CAGR (2026-2033)

Market Overview
Melanoma
Lung Cancer
Blood Cancer
Renal Cell Carcinoma
Prostate Cancer
Bladder Cancer
Others

Global Immuno-Oncology Drugs Market Size by Distribution Channel & CAGR (2026-2033)

Market Overview
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Global Immuno-Oncology Drugs Market Size & CAGR (2026-2033)

North America (Treatment Type, Disease Type, Distribution Channel)
- US
- Canada
Europe (Treatment Type, Disease Type, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Treatment Type, Disease Type, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Treatment Type, Disease Type, Distribution Channel)
- Brazil
- Rest of Latin America
Middle East & Africa (Treatment Type, Disease Type, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Coloplast Corp (Denmark)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol Myers Squibb Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GSK Plc. (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Fresenius Kabi AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Genentech Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bluebird Bio, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Regeneron Pharmaceuticals, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck KGaA (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ipsen (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments